These innovative compounds represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose https://tiannayrqk211252.isblog.net/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-56180569